Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Soon to be on demand: Advanced melanoma

Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted and immunotherapy. Now, there is finally five-year survival data for both kinds of treatments. How do these results impact daily clinical practice?

On January 21st from 20:30 until 21:30 MEDtalks broadcasts a unique e-learning, live from a studio in Brussels, wherein an expert panel led by prof. dr. Bart Neyns will discuss first- and second-line treatment of advanced melanoma with immuno and targeted therapy in patients with or without poor prognostic factors. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial will of course not be left untouched: should patients be treated with combination immunotherapy or monotherapy?

This programme will be available as an on-demand e-learning shortly afterwards. If you watch this live broadcast, you will be in the unique position to ask questions to the experts.

Panel members

  • Prof. Bart Neyns, MD, PhD, medical oncologist, University Hospital of Brussels
  • Prof. Vibeke Kruse, MD, PhD, medical oncologist, Ghent University Hospital
  • Annemie Rutten, MD, PhD, medical oncologist, GZA Hospital Sint-Augustinus, Antwerp
  • Prof. Dirk van Gestel, MD, PhD, radiation oncologist, Institut Jules Bordet

Subjects (among others)

  • Five-year survival rate for immune and targeted therapy;
  • First and second-line treatment of advanced melanoma;
  • Combination immunotherapy versus monotherapy antiPD1 followed by anti-CTLA4;
  • Management of patients with poor prognostic factors (e.g. brain metastases);

For this e-learning, accreditation will be arranged for medical oncologists in both Belgium and the Netherlands.

Target audience
Primary: Medical oncologists
Secondary: Radiotherapists, dermatologists, neurosurgeons and pathologists

  • Sponsors

    This program is editorially independent and is financially made possible by